Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Erik S. Knudsen(Southwestern Medical Center), Agnieszka K. Witkiewicz(Southwestern Medical Center)
Cited by 1
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
|Endocrine Related Cancer|2011|299
Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB Phosphorylation
|Molecular and Cellular Biology|1997|290
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
|Oncotarget|2014|211
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
|Journal of Clinical Investigation|2006|192